Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial-Reference-Cited by-同舟云学术

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

Published:2014-12-01 Issue:5 Volume:29 Page:1060-1068
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Schetelig J, ,Schaich M,Schäfer-Eckart K,Hänel M,Aulitzky W E,Einsele H,Schmitz N,Rösler W,Stelljes M,Baldus C D,Ho A D,Neubauer A,Serve H,Mayer J,Berdel W E,Mohr B,Oelschlägel U,Parmentier S,Röllig C,Kramer M,Platzbecker U,Illmer T,Thiede C,Bornhäuser M,Ehninger G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014335.pdf

Reference33 articles.

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.

2. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232–1240.

3. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK . Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006; 4: 445–451.

4. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658–3666.

5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349–2361.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial;The Lancet Haematology;2024-05

2. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches;Cancers;2024-02-05

3. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome;Blood Cancer Journal;2023-05-26

4. Remission Induction Versus Immediate Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Poor Responsive Acute Myeloid Leukemia (ASAP): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial;2023

5. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022;Bone Marrow Transplantation;2022-05-19